लोड हो रहा है...
Bevacizumab treatment for human glioblastoma. Can it induce cognitive impairment?
Recent results from 2 double-blind, placebo-controlled phase III trials (RTOG 0825) and (AVAglio) for first-line treatment of glioblastoma patients with the VEGF antibody bevacizumab, showed similar results, related to overall and progression-free survival. The RTOG 0825 trial indicated, opposed to...
में बचाया:
| मुख्य लेखकों: | , , , , , , , |
|---|---|
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
Oxford University Press
2014
|
| विषय: | |
| ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3984560/ https://ncbi.nlm.nih.gov/pubmed/24733853 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou013 |
| टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|